Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools

Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China

Liver disease constitutes a significant global health concern, particularly in China where it has distinctive characteristics. China grapples with a staggering 300 million cases, predominantly due to hepatitis B and metabolic non-alcoholic fatty liver disease. Additionally, hepatocellular carcinoma has become a prevalent which is a lethal type of cancer. Despite the scarcity of innovative treatment options, Chinese hepatologists and researchers have achieved notable breakthroughs in the prevention, diagnosis, management and treatment of liver diseases. Traditional Chinese medicines have found widespread application in the treatment of various liver ailments owing to their commendable pharmacological efficacy and minimal side effects. Furthermore, there is a growing body of research in extracellular vesicles, cell therapy and gene therapy, offering new hope in the fight against liver diseases. This paper provides a comprehensive overview of the epidemiological characteristics of liver diseases and the diverse array of treatments that Chinese scholars and scientists have pursued in critical field.

Quantitative evaluation of liver fibrosis based on ultrasound radio frequency signals: An animal experimental study

BACKGROUND

Chronic liver disease is an important cause of liver failure and death worldwide, and liver fibrosis is a common pathological process of most chronic liver diseases. There still lacks a useful tool for evaluating liver fibrosis progression precisely and non-invasively. The purpose of this study was to explore the use of ultrasound radio frequency (RF) signals combined with deep learning approach to evaluate the degree of liver fibrosis quantitatively.

METHODS

In this study, by extracting the output of deep learning models as a prediction value, a quantitative liver fibrosis prediction method was achieved based on the bidirectional long short-term memory (Bi-LSTM) network to analyze radio frequency (RF) signals. The dataset consisted of 160 sets of ultrasound RF signals of rat livers, including five fibrosis stages 0-4, upon pathological diagnosis. In total, 150 sets of RF signals were used to train four deep learning classification models, the output of which contained quantitative information. In each training stage of the four models, a large number of signal segments were extracted from the 150 sets and divided randomly into training and validation sets in a ratio of 80:20. Ten sets of RF data using the gold standard of quantitative fibrosis parameter (q-FP) of liver tissues were left for independent testing. To validate the proposed method, correlation analysis was carried out between q-FP and the quantitative prediction results based on the independent test data.

RESULTS

The accuracy of the four deep learning networks using the training and validation data was above 0.83 and 0.80, and the corresponding areas under the receiver operating characteristic curves were higher than 0.95 and 0.93, respectively. For the quantitative analysis in the independent test set, the determination coefficient, R², of the linear regression analysis between the quantitative prediction results and q-FP was above 0.93. liver fibrosis is a common pathological process of most chronic liver diseases.

CONCLUSIONS

This study indicates that a prediction system based on ultrasound RF signals and a deep learning approach is promising for realizing quantitative and visualized diagnosis of liver fibrosis, which would be of great value in monitoring liver fibrosis non-invasively.

Curcumin blunts epithelial-mesenchymal transition of hepatocytes to alleviate hepatic fibrosis through regulating oxidative stress and autophagy

The massive production and activation of myofibroblasts (MFB) is key to the development of liver fibrosis. In many studies, it has been proven that hepatocytes are an important part of MFB, and can be transformed into MFB through epithelial-mesenchymal transition (EMT) during hepatic fibrogenesis. In our previous study, we confirmed that curcumin inhibited EMT procession and differentiation of hepatocytes into MFB. In addition, in previous studies, it has been shown that autophagy plays an important role in the regulation of cellular EMT procession. In the current study, we showed that curcumin inhibited TGF-β/Smad signaling transmission by activating autophagy, thereby inhibiting EMT. The mechanism of degradative polyubiquitylation of Smad2 and Smad3 is likely through inhibiting tetratricopeptide repeat domain 3 (TTC3) and by inducing ubiquitylation and proteasomal degradation of Smad ubiquitination regulatory factor 2 (SMURF2), which on account of the increase of autophagy in hepatocytes. Curcumin inhibits levels of reactive oxygen species (ROS) and oxidative stress in hepatocytes by activating PPAR-α, and regulates upstream signaling pathways of autophagy AMPK and PI3K/AKT/mTOR, leading to an increase of the autophagic flow in hepatocytes. In this study, we confirm that curcumin effectively reduced the occurrence of EMT in hepatocytes and inhibited production of the extracellular matrix (ECM) by activating autophagy, which provides a potential novel therapeutic strategy for hepatic fibrosis.

Hepatic cirrhosis according to the forensic medical autopsy data from Moscow for the period of 2007-2016

Study purpose is to demonstrate the dynamics of mortality due to hepatic cirrhosis according to forensic medical autopsy data over the period from 2007 to 2016. Material and methods ― 268,139 protocols of forensic autopsies were studied to identify the number of deaths by hepatic cirrhosis over ten years between 2012 and 2016 and to determine the number of cases of liver failure associated with cirrhosis. To clarify the dynamics of mortality due to hepatic cirrhosis, a comparative analysis of two chronologically consecutive five-year periods, 2007-2011 and 2012-2016, has been conducted. The age of deceased by hepatic cirrhosis was studied. The number of cases with a histologically verified form of hepatic cirrhosis was specified. The average values and the percentage ratio of the number of examinations performed to the total number of all autopsies for non-violent death cases were calculated. Results ― Over ten years of study, death by hepatic cirrhosis was diagnosed 3,092 times, including 749 times with histologically confirmed liver failure. In 2009, there was an abrupt increase in mortality due to hepatic cirrhosis by the factor of 3.8, and the lowest mortality level was found in 2016. When comparing the mentioned two quinquennia, the first of them, 2007-2011, was characterized by an increase in the number of diagnosed hepatic cirrhosis. During the second one, 2012-2016, on the contrary, the dynamics of a decrease in the number of hepatic cirrhosis was revealed. At the average, the annual decrease in the number of hepatic cirrhosis diagnosed during the forensic medical examinations of corpses was 7.7%. The number of established cases of liver failure during the first five-year period compared with the data on the second one was significantly greater. In 2010, there were 109 such cases, in 2016 only 13. Among the histologically verified diagnoses, micronodular and mixed forms of hepatic cirrhosis prevailed. Most of the cases of hepatic cirrhosis were found in men aged within 31-40. Conclusion ― It has been found that over the past five years there has been a shift in the forensic-medical mortality values due to hepatic cirrhosis from the increasing trend to the decreasing one. If within the period of 2007-2011 an increase in diagnosed hepatic cirrhosis was observed, then during 2012-2016 a pronounced decreasing tendency in the number of such diagnoses was disclosed. During that time the number of histologically verified cases of hepatic failure decreased by 43.0%. As a cause of death, hepatic cirrhosis was more often recorded in men aged within 30–40.

Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B

Monitoring longitudinal nonadvanced fibrosis is a more common scenario in management of chronic hepatitis B (CHB), for which, however, current evaluation methods generally lack sufficient performance. We conducted a proof-of-concept study to evaluate the performance of quantitative fibrous collagen parameters (q-FP) in the assessment. Data sets from a prior CHB trial (NCT00962533) with mostly mild-to-moderate fibrosis participants were used for this study. 301 subjects with paired liver biopsies were consecutively included. Of these, 139 subjects were used to establish the test and the rest for internal validation. Fibrosis change between baseline and week 104 of treatment was blindly assessed with q-FP and was compared with Ishak fibrosis staging. There were 70% and 93% subjects with Ishak F0-2 at baseline and week 104, respectively. For the test of the subjects, q-FP and Ishak staging showed no difference in determining the incidence of fibrosis regression (68% vs 67%; difference = 0.7%, P = 1.00). Q-FP demonstrated that the regression was independently associated with the antiviral efficacy endpoint (OR 3.0, 95% CI 1.4-6.5, P = .005), but Ishak failed the detection (OR 0.6, 95% CI 0.3-1.3, P = .24). Moreover, q-FP directly revealed a higher fibrosis-resistance to antiviral treatment in virus genotypes C vs B and in males vs females. These results were confirmed in the validation subjects. Additionally, a functional model built on the test subjects showed an accuracy of 82% in stratifying fibrosis reversibility of the validation subjects. In conclusion, q-FP could have improved efficiency and accuracy in the longitudinal assessment of mild-to-moderate CHB fibrosis, indicating a potential alternative to current evaluation methodologies.

Pokeweed antiviral protein attenuates liver fibrosis in mice through regulating Wnt/Jnk mediated glucose metabolism

BACKGROUND/AIMS

Pokeweed antiviral protein (PAP) has been reported to downregulate Wnt/Jnk pathway and attenuate liver fibrosis. This study was designed to intensively explore the mechanism of anti-fibrosis effect of PAP.

MATERIALS AND METHODS

Hepatic stellate cell (HSC) activation was induced by high concentration of glucose. Cell viability was detected at different time points after PAP treatment. Meanwhile, hepatic fibrosis models in mice were induced by CCl4 injection. In the end, liver pathology was observed and contents of alanine transaminase, aspartate transaminase, lactic dehydrogenase, hyaluronic acid (HA), and laminin (LN) in serum together with hydroxyproline (Hyp) in liver were measured. The mRNA and protein expressions of HK2, PFKP, PCK1, and FBP1 as well as Jnk expression in HSC-T6 cells and liver tissue were detected by qPCR and western-blot, respectively.

RESULTS

Compared with high glucose, PAP reduced viability and expressions of HK2, PFKP, α-SMA, and Col1A1, where as enhanced the expressions of PCK1 and FBP1 in HSC-T6 cells (P < 0.05) respectively. PAP attenuated liver pathology, improved liver function, and reduced collagen deposition in liver tissue compared with the model group (P < 0.05) respectively. Moreover, PAP reduced expressions of HK2, PFKP, α-SMA, and Col1A1 where as increased the expression of PCK1 and FBP1 in the liver of mice compared with the model group (P < 0.05) respectively. Most importantly, PAP reduced the phosphorylation of Jnk both in cells and liver tissue compared with the model group (P < 0.05) respectively.

CONCLUSIONS

Our results demonstrated that PAP attenuated liver fibrosis by regulating Wnt/Jnk-mediated glucose metabolism. It provided us a new target for the treatment of liver fibrosis.

Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection

Transient elastography (TE) is accurate in staging fibrosis noninvasively. However, a reliable serum biomarker with comparable accuracy is also important, especially when TE is unreliable/unavailable. Therefore, we aimed to evaluate the diagnostic performance of serum Golgi protein 73 (GP73) for significant fibrosis in patients with chronic HBV infection. A total of 801 patients with chronic liver disease (CLD; 492 chronic HBV infection and 309 non-HBV liver disease) with liver biopsy performance were enrolled. Healthy controls (n = 180) and hepatocellular carcinoma (HCC) patients (n = 85) were included for comparisons. Liver biopsy was used as the reference method for fibrosis staging. Serum GP73 level was measured in duplicate in double-blind fashion. Serum GP73 was highest in HCC but also significantly higher in chronic hepatitis B than in healthy controls. The elevation of serum GP73 in non-HCC patients was significantly associated with the presence of significant fibrosis independently of ALT level, liver stiffness (LS) value, inflammation grade and other confounding factors. The diagnostic performance of serum GP73 was accurate in antiviral-naïve HBV patients (area under the receiver operating curve [AUROC], 0.76 95% CI: 0.72-0.81) but not in patients with ongoing antiviral treatment (AUROC, 0.60). The utility of serum GP73 was also confirmed in non-HBV CLD (AUROC, 0.80 95% CI: 0.75-0.85). Serum GP73 was comparable to LS (AUROC, 0.78 95% CI: 0.73-0.82) and significantly better than AST to platelet ratio index (APRI) (AUROC, 0.67 95% CI: 0.62-0.72) and FIB-4 (AUROC, 0.68 95% CI: 0.63-0.73). In conclusion, serum GP73 is an accurate serum marker for significant fibrosis in chronic HBV infection, with higher accuracy than APRI and FIB-4. Serum GP73 is potentially a complementary tool for TE when evaluating the necessity of antiviral treatment, particularly in patients without definite antiviral indication.

Long-term effects of human amniotic membrane in a rat model of biliary fibrosis

Liver fibrosis is the most common outcome of chronic liver diseases, and its progression to cirrhosis can only be effectively treated with liver transplantation. The amniotic membrane (AM) has been studied as an alternative therapy for fibrosis diseases mainly for its favorable properties, including anti-inflammatory, anti-scaring and immunomodulatory properties. It was recently demonstrated that the AM reduces the progression of biliary fibrosis to its advanced stage, cirrhosis, when applied on the liver for 6 weeks after fibrosis induction. Here, we investigated the effects of AM on rat fibrotic liver, during a prolonged period of time. Fibrosis was induced by bile duct ligation (BDL), and at the same time, a fragment of AM was applied around the liver. After 1, 3, 6, and 9 weeks, the degree of fibrosis was assessed by qualitative Knodell scoring, and by quantitative image analysis to quantify the area of collagen deposition in hepatic tissue. While fibrosis progressed rapidly in untreated BDL animals, leading to cirrhosis within 6 weeks, AM-treated livers showed confined fibrosis at the periportal area with few and thin fibrotic septa, but without cirrhosis. In addition, collagen deposition was reduced to about 36 and 55% of levels observed in BDL at 6 and 9 weeks after BDL, respectively, which shows that the longer the period of AM application, the lower the collagen deposition. These results suggested that AM applied as a patch onto the liver surface for longer periods attenuated the severity of biliary fibrosis and protected against liver degeneration caused by excessive collagen deposition.